Logo small

Pharmacotherapy for SMA in children benefits all patients

MedExpress Team

Piotr Wójcik

Published Nov. 7, 2022 12:33

Pharmacotherapy for SMA in children benefits all patients - Header image
- The minimum plan is to stop the progression of the disease. This was achieved in all patients. Almost 90 percent of improvement was achieved, which in the progressive disease of the nervous system is completely unattainable without treatment - said in an interview with Medexpress Prof. Katarzyna Kotulska-Jóźwiak, head of the Department of Neurology and Epileptology at the Monument Institute - Mother and Child Health Center.

In the report "Spinal Muscular Atrophy and Treatment of SMA in Poland. New quality of life for patients and carers ”, the first data from real clinical observation for pediatric groups are presented. How would you summarize the results of this observation?

First of all, we have a very large group of children whose treatment was successfully summarized. This is a group of 298 patients, of which only six did not complete the first year of treatment. The rest of the group, i.e. 292 children, continued treatment longer. It is a treatment that can be kept safe and effective for a long time. We have not had any case of a child whose treatment had to be discontinued due to intolerance. We also did not have any case of a child who met the criteria of therapy failure. Such criteria include failu...

Content locked

To gain access to the complete English section of the, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Read also